Press Releases Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Real-time Estimate Cboe BZX Other stock markets 12:40:37 17/05/2024 am IST			5-day change	1st Jan Change
45.21 ^USD	0.00%		-5.35%	+12.02%

13/05	Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating	MT
10/05	Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Soleno Therapeutics Stands with the Prader-Willi Syndrome Community	15/05	AQ
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	10/05	AQ
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock	03/05	AQ
Soleno Therapeutics Announces Proposed Public Offering of Common Stock	03/05	AQ
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome	30/04	AQ
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)	29/04	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - April 19, 2024	22/04	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/04	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	09/03	AQ
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results	07/03	AQ
Soleno Therapeutics : March 2024 Corporate Presentation	04/03	PU
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference	22/02	AQ
Soleno Therapeutics to Present at Upcoming February Investor Conferences	01/02	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	30/01	AQ
Soleno Therapeutics Strengthens Leadership Team with Key Appointments	24/01	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/01	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	11/11	AQ
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results	07/11	AQ
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome	06/11	AQ
PWS children who switch from DCCR see worsening hyperphagia: Trial	06/23/06	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Press Releases

Filters